The shadow of generic competition has consistently loomed above copyright’s iconic drug, Viagra, raising questions about the future of connected pharmaceutical investments. While early years saw significant profits, the patent lapse has opened the door for discounted copies, potentially diminishing profitability and creating a genuine risk for st